Inlecitug

因莱西塔单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameInlecitug
Drug Alias NameGentuximab金妥昔单抗
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChangchun GeneScience Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChangchun GeneScience Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms +[4] 
Inactive IndicationsSolid tumoursEsophageal NeoplasmsGastrointestinal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A